[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-352915-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-352915-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","utilizing-drugs-food-and-natural-product-libraries-a-computational-approach-to-targeting-pgam1-in-clinical-cancer-therapy","Utilizing drugs, food, and natural product libraries - A computational approach to targeting PGAM1 in clinical cancer therapy","","Phosphoglycerate mutase 1 (PGAM1) is a key glycolytic enzyme whose upregulation supports cancer metabolism, tumor growth, and progression, making it an attractive drug-development target. A structure-based virtual screening workflow was used to screen drugs, food, and natural compound libraries against PGAM1, followed by docking and interaction analyses. The top hits were subjected to 200 ns molecular dynamics simulations to assess stability. Results indicate stable protein–ligand interactions with no substantial conformational changes during simulation, suggesting lead potential while requiring further experimental validation.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/utilizing-drugs-food-and-natural-product-libraries-a-computational-approach-to-targeting-pgam1-in-clinical-cancer-therapy/352915/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/utilizing-drugs-food-and-natural-product-libraries-a-computational-approach-to-targeting-pgam1-in-clinical-cancer-therapy/352915.png","ImageObject",300,407,{"name":42,"@type":43},"Chumphorn","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-06","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is PGAM1 considered a promising target in cancer therapy?","Question",{"text":63,"@type":64},"PGAM1 is an important glycolytic enzyme involved in cancer metabolism. Its abnormal expression supports tumor growth and progression by coordinating glycolysis with anabolic processes and influencing metabolic pathways.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What computational strategy was used to identify potential PGAM1 inhibitors?",{"text":68,"@type":64},"Drugs, food, and natural compound libraries were screened against PGAM1 using structure-based virtual screening, followed by docking. Binding affinities guided selection of top compounds for molecular interaction analysis and later molecular dynamics simulation.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the molecular dynamics simulations show about the selected hits?",{"text":72,"@type":64},"The top compounds maintained stable interactions with PGAM1 during 200 ns simulations. No significant conformational changes in the protein structure were observed, supporting the hits as lead candidates.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},352915,1790215694,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":33,"preview_urls":145},2336475401981,"https://ap-avatar.wpscdn.com/avatar/22000c94efd8d5204d?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786935347598174694","®  \n Observational Study   \nUtilizing drugs, food, and natural product libraries A computational approach to targeting PGAM1 in clinical cancer therapy  \nAbdullah R. Alanzi, PhDa ,* , Hattan A. Alharbi, PhDa  \n\n| Abstract\u003Cbr>Phosphoglycerate mutase 1 (PGAM1) is an important glycolytic enzyme that plays a significant role in cancer metabolism. It catalyzes the conversion of 3-phosphoglycerate (3-PG) to 2-phosphoglycerate (2-PG), facilitating energy release during glycolysis. PGAM1 is often upregulated in various cancers, including breast, lung, and prostate cancers, contributing to tumor growth and progression by coordinating glycolysis and anabolic processes which makes it an appealing target for drug development. In this study, we screened drugs, food, and natural compound libraries against PGAM1 by using structure based virtual screening approach. A total of 100 compounds from each library were screened and then docked to find the best plausible modes of the hits. Based on the binding affinities, 5 compounds from each library were selected for molecular interactions analysis. After analyzing the interactions, the top compound from each library was subjected to 200 ns simulation to check the effect of hitson the protein. The simulation results revealed that the hits made stable interactions with the protein during simulation and no confirmational changes were observed in the structure of protein. All these findings suggest that the selected compounds can serve as lead compounds in inhibiting the biological activity of PGAM1, but it requires further experimental investigation. Abbreviations: OPLS = optimized potentials for liquid simulations, PDB = Protein Data Bank, PGAM1 = phosphoglyceratemutase 1, RMSD = root mean square deviation, RMSF = root mean square fluctuation, SBDD = structure-based drug design. |\n| --- |\n| Keywords: Cancer, molecular docking, molecular dynamics (MD) simulation, PGAM1 , virtual screening |\n\n1. Introduction  \nPhosphoglycerate mutase 1 (PGAM1) is an essential enzyme in glycolysis, as it catalyzes the conversion of 3-phosphoglycerate (3-PG) into 2-phosphoglycerate (2-PG), it is an essential part of the metabolic network. Apart from regulating the rate at which glycolysis proceeds and the way sugar is taken up, broken down, and converted into energy inside cancer cells, PGAM1 also regulates the amounts of 3-PG and 2-PG, which therefore affects the functions of other enzymes and metabolic pathways. The expression of PGAM1 is abnormal in many cancers, which promotes the growth and spread of cancer cells and eventually affects the prognosis of malignancy. PGAM1 has thus emerged as a key target in anti-tumor research. [1–4]  \nCurrentl, the PGMI-004A, MJE3, and the naturally occurring compound epigallocatechin gallate (EGCG), which is mostly derived from Camellia sinensis (green tea) and derivatives of xanthones, are among the few known PGAM1 inhibitors. [5] MJE3 was first discovered to be a PGAM1 inhibitor; however, due to its spiroepoxide substructure, it also covalently modifies the K100 residue of PGAM1 to render it inactive. [6] A proven PGAM1 inhibitor, PGMI-004A has anticancer effects in mice models with tumors xenografted from humans. The  \ndescribed inhibitors’ molecular potencies are both insignificant.[7] Despite having a molecular potency thirty times greater than PGMI-004A, EGCG, PGAM1’s third inhibitor, cannot be regarded as a good inhibitor because to its off-target effects and polyphenol structure. [6] To suppress PGAM1 activity, xanthone derivatives (24 N-xanthone benzene sulfonamides) have recently been developed and synthesized. When compared to PGMI-004A, the majority of them show mild anti-proliferation effects on various cancer cell lines and better effectiveness against PGAM1 . [8,9] It is necessary to create and find additional active substances that can bind to the PGAM1 enzyme and limit its metabolic activity because there aren’t many known PGAM1 inhibitors.  \nStructure-based drug d","cbCaigyj0aMmJ2wj","https://ap.wps.com/l/cbCaigyj0aMmJ2wj","pdf",3905006,12,"English","# Introduction\n## Target rationale: PGAM1 in cancer metabolism\n## Known PGAM1 inhibitors and limitations\n## Structure-based drug design (SBDD) approach","[{\"question\":\"Why is PGAM1 considered a promising target in cancer therapy?\",\"answer\":\"PGAM1 is an important glycolytic enzyme involved in cancer metabolism. Its abnormal expression supports tumor growth and progression by coordinating glycolysis with anabolic processes and influencing metabolic pathways.\"},{\"question\":\"What computational strategy was used to identify potential PGAM1 inhibitors?\",\"answer\":\"Drugs, food, and natural compound libraries were screened against PGAM1 using structure-based virtual screening, followed by docking. Binding affinities guided selection of top compounds for molecular interaction analysis and later molecular dynamics simulation.\"},{\"question\":\"What did the molecular dynamics simulations show about the selected hits?\",\"answer\":\"The top compounds maintained stable interactions with PGAM1 during 200 ns simulations. No significant conformational changes in the protein structure were observed, supporting the hits as lead candidates.\"}]","Utilizing drugs, food, and natural product libraries - A computational approach to targeting PGAM1 in clinical cancer therapy | PDF",1790101969,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c147cc556ea82d5fe4c45b7810a04fd6.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5fe70e6861a08270854bf42d10d56f01.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f49bd218d8a38f5953d1caa4465437b3.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1c887d76eaf2b281c4735823ad775806.webp",980,1306]